AzTrials
AzTrials

Congenital Heart DiseaseNCT01572363

Fontan Patients: Comprehensive Evaluation of Pulmonary Circulation and Ventricular Function

A study testing Sildenafil in people with Congenital Heart Disease, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In patients with one anatomical or functional ventricular chamber, which encompasses a spectrum of rare and complex congenital cardiac malformations, a staged surgical approach in view of an ultimate Fontan operation has become the procedure of choice. Read more about this study

Who is it for?
Ages 14 years and older
Conditions the study is for
Congenital Heart Disease
What is being tested?
Sildenafil
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteBelgium
Study dates
Apr 2012to Mar 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • ≥ 14 years of age
  • Written informed consent
  • Fontan pathology

Who cannot join

  • Inability to performe exercise
  • Contra-indication for MR evaluation

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • University Hospitals Leuven

    Leuven, Vlaams-Brabant, 3000

Other trials in Belgium

About this study

Official title: Fontan Patients: Comprehensive Evaluation of the Pulmonary Circulation to Identify Pulmonary Vascular Disease and Its Influence on Ventricular Hemodynamics.

In patients with one anatomical or functional ventricular chamber, which encompasses a spectrum of rare and complex congenital cardiac malformations, a staged surgical approach in view of an ultimate Fontan operation has become the procedure of choice. Especially in the earlier era, perioperative mortality was the leading cause of death. However, many patients have a long and high-quality life, continuously improved by a better understanding of Fontan hemodynamics and the refinement of the surgical procedures. Nevertheless, the prospect of eventual failure of the Fontan circulation remains a major concern. More specifically, evaluation of the pulmonary circulation becomes particularly important as the failing Fontan circulation has become a common indication for cardiac transplantation. Although essential, especially in the preoperative setting, a comprehensive evaluation of the pulmonary circulation remains difficult in this patient population

Our global hypothesis is that the absence of pulsatile pulmonary flow may lead to the development of pulmonary vascular lesions after the Fontan operation and that - together the absence of a subpulmonary ventricle for pressure generation - this increasing afterload will result in systemic ventricular underfilling and will eventually lead to a failing Fontan circulation.

Read the detailed description

Background

In patients with one anatomical or functional ventricular chamber, which encompasses a spectrum of rare and complex congenital cardiac malformations, a staged surgical approach in view of an ultimate Fontan operation has become the procedure of choice. Especially in the earlier era, perioperative mortality was the leading cause of death. However, many patients have a long and high-quality life, continuously improved by a better understanding of Fontan hemodynamics and the refinement of the surgical procedures. Nevertheless, the prospect of eventual failure of the Fontan circulation remains a major concern. More specifically, evaluation of the pulmonary circulation becomes particularly important as the failing Fontan circulation has become a common indication for cardiac transplantation. Although essential, especially in the preoperative setting, a comprehensive evaluation of the pulmonary circulation remains difficult in this patient population.

Different types of Fontan circulation

Atriopulmonary connection

In the atriopulmonary connection, the right atrium is interposed as a valveless contractile chamber between the systemic venous and pulmonary arterial bed. Although initially believed to be beneficial, the interposition of such a valveless pulsatile chamber does not contribute positively to fluid energy. Moreover, pulsation results at the price of higher upstream pressures, whereas downstream pressures remain unchanged.

Total cavopulmonary shunts

This procedure consists of diverting the superior vena cava return into the pulmonary arteries and connecting the vena cava inferior to the pulmonary arteries. This action is achieved either by the construction of a composite conduit made of the sinus venarum and a prosthetic patch (intracardiac total cavopulmonary connection or lateral tunnel) or by an extracardiac conduit (extracardiac total cavopulmonary connection).

Our global hypothesis is that the absence of pulsatile pulmonary flow may lead to the development of pulmonary vascular lesions after the Fontan operation and that - together the absence of a subpulmonary ventricle for pressure generation - this increasing afterload will result in systemic ventricular underfilling and will eventually lead to a failing Fontan circulation.

Fontan attrition

The systemic ventricle

Although preload reduction may lead to inappropriate ventricular hypertrophy, with concomitant ventricular relaxation problems and a decreased capacity for adaptation to increased afterload, it is generally accepted that the pulmonary vasculature is more important than mild ventricular dysfunction in this patient population. Naturally, severe ventricular dysfunction will affect patient's prognosis.

The pulmonary circulation

The absence of a right ventricular to pulmonary arterial coupling has a profound influence on systemic venous return and the pulmonary circulation. Several aspects have to be taken into account when evaluating the pulmonary circulation

  1. Systemic venous pressure. Systemic venous pressures, which are approximately 5 mmHg in healthy controls at rest and remains unchanged during exercise, are higher in Fontan patients. In Fontan patients, the absence of a right ventricle for pressure generation, some degree of congestion is required in order to force transpulmonary flow. However, at rest pressures above 20 mmHg are rarely seen as such pressures would lead to complications (oedema, pleural effusions and ascites). Interestingly, pressure change observed during exercise in normals and Fontan patients is quite similar. In healthy controls, an increase in mean pulmonary artery pressure from 15 mmHg at rest to 30 mmHg during exercise. In Fontan patients, mean right atrial pressure increased from 15 mmHg at rest to 25 mmHg during exercise.
  2. Left atrial pressure. In healthy controls, left atrial pressures shows little variability at rest and is mainly determined by the atrioventricular valve and ventricular dysfunction. In Fontan patients, diastolic parameters are more difficult to assess as preload insufficiency should be considered.8 During exercise, left atrial pressure normally remains stable or increases somewhat in healthy individuals. However, there are few data available on left atrial pressures during exercise in Fontan patients.
  3. Pulmonary circulation

Although there is still no unequivocal proof, several authors indicated that PVR appears to be the major determinant of cardiac output in Fontan patients at rest and during exercise. A low PVR is even more important in these patients as they do not have the possibility for adapting to a higher afterload, whereas in patients with a subpulmonary ventricle, increased afterload will be countered by RV hypertrophy. It has been suggested that Fontan patients having low PVR remain stable for many decades, whereas a high PVR appears to be poor prognostic factor.

Measurement of PVR and problems in Fontan patients

Most commonly, PVR is measured using the Fick method based on the principle that a known amount of a specific indicator is added to a volume of fluid. If the concentration before and after this addition is known, the volume of fluid can be calculated. The Fick method uses the physiological uptake of oxygen as an indicator. However, this method may be inaccurate in this patient population. Other techniques, such as the dye dilution technique or thermodilution technique suffer from their own limitations, such as reduced reliability in the presence of shunts or valvular regurgitation.

In order to provide a more accurate measurement of PVR, a combined approach of invasive pressure measurements and velocity-encoded magnetic resonance has become available, and has proven to be feasible in different patient populations. Cardiac output measured using this approach has been shown to be accurate and feasible in Fontan patients. Moreover, flow through to left and right pulmonary artery can be measured separately.

Measurement of PVR and ventricular volumes during exercise

As mentioned earlier, transpulmonary flow in Fontan patients is dependent on the presence of low PVR and normal behavior of PVR during exercise in order to be able to increase cardiac output. An increase in PVR during exercise would cause a more pronounced underfilling of the systemic ventricle with subsequently less increase or even decrease in stroke volume. Both pressure and flow measurements have been shown feasible in patients with congenital heart disease at rest and during exercise.

Measurement of PVR and ventricular volumes after vasodilatation Several studies have shown that drugs affecting the pulmonary vasculature (sildenafil, bosentan, NO) reduce PVR and increase cardiac output in selected patients. Especially in patients with elevated PVR, these drugs have the potential to decrease PVR and increase ventricular volumes, cardiac output and exercise tolerance. Whether these drugs improve outcome remains to be evaluated.

Aims of the study

Feasibility of measuring PVR in Fontan patients using simultaneous acquisition of invasive pressures and MR flow data.

Effect of Sildenafil 50 mg on PVR, ventricular volume and function at rest

Effect of bicycle stress on PVR, ventricular volume and function

Evaluating the reliability of bicycle stress echocardiography in determining ventricular volume and function as an indirect parameter reflecting the status of the pulmonary vasculature

Being tested
Sildenafil
Keywords
Fontan, Cardiac magnetic resonance imaging, Sildenafil
Medical subject headings
Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SildenafilDrug

    Also called Viagra, Revatio

    50 mg once

Study groups in NCT01572363
Study groupRoleWhat they receive
SildenafilExperimentalAll patients will be given Sildenafil 50 mg with evaluation of pulmonary vascular resistance and systemic ventricular function at rest and during exercise after 30 minutes.
Receives: Drug: Sildenafil

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Systemic ventricular stroke volume during exercise

    Systemic ventricular stroke volume during exercise as evaluated using bicycle stress magnetic resonance imaging.

    Measured: 30 minutes after administration of sildenafil

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Apr 2012 (estimated)
  2. Study startApr 2012
  3. Primary completionMar 2014
  4. Study completionMar 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01572363
Sponsor's protocol ID
ML6721
Status last verified
Mar 2014
First submitted
3 Apr 2012
Last updated
5 Mar 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Sildenafil in people with Congenital Heart Disease, run by Universitaire Ziekenhuizen KU Leuven at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Systemic ventricular stroke volume during exercise (time frame: 30 minutes after administration of sildenafil). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2014.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in